Genmab — Juli 2017
-
God morgen.
-
Godmorgen
-
Er der nogen der ved om ledelsen/medarbejderne har warrant som de kan sælge i august måned?
-
Hvis det er på samme måde som de andre år omkring halvårs regnskab, så fslder kursen godt. Måske man skulle sælge lidt og fiske lidt bagefter
-
falder kursen:-)
-
Beklager min fejl information. Det Michael Novod har informeret at M.M markedet vil være ca. 9B USD i 2020 og det er sikkert revideret efter denne artikel fra 2013 http://www.firstwordpharma.com/node/1066623?tsid=21#axzz4oOXUDX45
-
The global multiple myeloma therapeutics market was valued at USD 7.5 billion in 2015 and is expected to reach a value of USD 37.5 billion by 2024. Key factors driving the market expansion include constant introduction of newer and effective therapeutic options and high adoption rates of the same.
-
-
-
Der er an meget afventende handel med Genmap. Er det mon udtryk for en afventen med hensyn til halvårsregnskabet den 9. Aug?
-
OK
-
-
God eftermiddag. Der er nok at glæde sig til i den kommende tid: Q3-2017: Darzalex ph III ALCYONE frontline MM data with Velcade
H2 2017: ESMO Congress – 8-12 September
H2 2017: Ph II data for Tisotumab Vedotin (likely at ESMO)
H2 2017: Darzalex Ph II data in high-risk smouldering myeloma
(CENTAURUS study) likely in Q4 (ASH)
H2 2017: Darzalex ph II data in multiple myeloma with Celgene’s
durvalumab
H1 2018: Darzalex ph III MAIA frontline MM data with Revlimid
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind